Evidence map›Paper›PMID 32509176›Full record

ArticleAmerican journal of translational research2020

Compound A inhibits urothelial tumorigenesis via both the androgen receptor and glucocorticoid receptor signaling pathways.

Hiroki Ide, Satoshi Inoue, Taichi Mizushima, Guiyang Jiang, Yujiro Nagata, Takuro Goto, Eiji Kashiwagi, Hiroshi Miyamoto

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. The androgen receptor in bladder cancer.Nature reviews. Urology · 2023
    Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hiroki IdeDepartment of Pathology, Johns Hopkins University School of Medicine Baltimore, MD, USA.
Satoshi InoueDepartment of Pathology, Johns Hopkins University School of Medicine Baltimore, MD, USA.
Taichi MizushimaDepartment of Pathology, Johns Hopkins University School of Medicine Baltimore, MD, USA.
Guiyang JiangDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center Rochester, NY, USA.
Yujiro NagataDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center Rochester, NY, USA.
Takuro GotoDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center Rochester, NY, USA.
Eiji KashiwagiDepartment of Pathology, Johns Hopkins University School of Medicine Baltimore, MD, USA.
Hiroshi MiyamotoDepartment of Pathology, Johns Hopkins University School of Medicine Baltimore, MD, USA.
Johns Hopkins University · USJohns Hopkins Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent preclinical evidence has indicated that both androgen receptor (AR) inactivation and glucocorticoid receptor (GR) transrepression are associated with suppression of urothelial carcinogenesis. We therefore assessed the effect of a unique compound, 2-(4-acetoxyphenyl)-2-chloro-N-methylethylammonium chloride (Compound A; CpdA), which could function as an AR antagonist as well as a GR ligand, on urothelial tumorigenesis. Using the

Indexed as

Anti-androgendexamethasonemalignant transformationprednisoneurothelial cancer

Identifiers

PMID32509176
PMCPMC7270017
OpenAlexW3033986370

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.